Knight Therapeutics Inc. (OTCMKTS:KHTRF) Sees Large Decline in Short Interest

Knight Therapeutics Inc. (OTCMKTS:KHTRFGet Rating) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 123,500 shares, a decline of 5.6% from the February 13th total of 130,800 shares. Based on an average trading volume of 6,300 shares, the short-interest ratio is presently 19.6 days.

Knight Therapeutics Price Performance

KHTRF stock opened at $3.65 on Friday. Knight Therapeutics has a 52 week low of $3.65 and a 52 week high of $4.77. The company’s 50-day moving average price is $3.85 and its 200 day moving average price is $4.00.

About Knight Therapeutics

(Get Rating)

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Further Reading

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.